Mark Fishbein

Mark Fishbein

Auto-generated profile, based on publicly available information

Mark Fishbein

Department of Pediatrics Ann & Robert H. Lurie Children′s Hospital of Chicago Chicago Illinois USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TWTinsay A. Woreta
Tinsay A. Woreta
MNMark L. Van Natta
Mark L. Van Natta
MLMariana Lazo
Mariana Lazo
AKArunkumar Krishnan
Arunkumar Krishnan
BNBrent A. Neuschwander-Tetri
Brent A. Neuschwander-Tetri
FNfor the NASH Clinical Research Network
for the NASH Clinical Research Network
Background and aims: Management of patients with NASH who are at elevated risk of progressing to complications of cirrhosis (at-risk NASH) would be enhanced by an accurate, noninvasive diagnostic test. The new FAST™ score, a combination of FibroScan® parameters liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) and aspartate aminotransferase (AST), has shown good diagnostic accuracy for at-risk NASH (area-under-the-Receiver-Operating-Characteristic [AUROC] = 0.80) in European cohorts. We aimed to validate the FAST™ score in a North American cohort and show how its diagnostic accuracy might vary by patient mix. We also compared the diagnostic performance of FAST™ to other non-invasive algorithms for the diagnosis of at-risk NASH. Methods: We studied adults with biopsy-proven non-alcoholic fatty liver disease (NAFLD) from the multicenter NASH Clinical Research Network (CRN) Adult Database 2 (DB2) cohort study. At-risk-NASH was histologically defined as definite NASH with a NAFLD Activity Score (NAS) ≥ 4 with at least 1 point in each category and a fibrosis stage ≥ 2. We used the Echosens® formula for FAST™ from LSM (kPa), CAP (dB/m), and AST (U/L), and the FAST™-based Rule-Out (FAST™ ≤ 0.35, sensitivity = 90%) and Rule-In (FAST™ ≥ 0.67, specificity = 90%) zones. We determined the following diagnostic performance measures: AUROC, sensitivity (Se), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV); these were calculated for the total sample and by subgroups of patients and by FibroScan® exam features. We also compared the at-risk NASH diagnostic performance of FAST™ to other non-invasive algorithms: NAFLD fibrosis score (NFS), Fibrosis-4 (FIB-4) index, and AST to platelet ratio index (APRI). Results: The NASH CRN population of 585 patients was 62% female, 79% white, 14% Hispanic, and 73% obese; the mean age was 51 years. The mean (SD) AST and ALT were 50 (37) U/L and 66 (45) U/L, respectively. 214 (37%) had at-risk NASH. The AUROC of FAST™ for at-risk NASH in the NASH CRN study population was 0.81 (95% CI: 0.77, 0.84. Using FAST™-based cut-offs, 35% of patients were ruled-out with corresponding NPV = 0.90 and 27% of patients were ruled-in with corresponding PPV = 0.69. The diagnostic accuracy of FAST™ was higher in non-whites vs. whites (AUROC: 0.91 vs 0.78; p = 0.001), and in patients with a normal BMI vs. BMI > 35 kg/m2 (AUROC: 0.94 vs 0.78, p = 0.008). No differences were observed by other patient characteristics or FibroScan® exam features. The FAST™ score had higher diagnostic accuracy than other non-invasive algorithms for the diagnosis of at-risk NASH (AUROC for NFS, FIB-4, and APRI 0.67, 0.73, 0.74, respectively). Conclusion: We validated the FAST™ score for the diagnosis of at-risk NASH in a large, multi-racial population in North America, with a prevalence of at-risk NASH of 37%. Diagnostic performance varies by subgroups of NASH patients defined by race and obesity. FAST™ performed better than other non-invasive algorithms for the diagnosis of at-risk NASH.

18 September 2012 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
MFMark Fishbein
Mark Fishbein
CBChristina Branham
Christina Branham
CFCheryl Fraker
Cheryl Fraker
LWLaura Walbert
Laura Walbert
SCSibyl Cox
Sibyl Cox
DSDonna Scarborough
Donna Scarborough

3 January 2025 in Hepatology
Verified
Journal Article
Closed access
KNKimberly P. Newton
Kimberly P. Newton
DJDulshan Jayasekera
Dulshan Jayasekera
ABAmanda Blackford
Amanda Blackford
CBCynthia Behling
Cynthia Behling
LWLaura A. Wilson
Laura A. Wilson
FCFor The Nash Crn
For The Nash Crn
Background and Aims: Longitudinal outcomes in children with metabolic dysfunction–associated steatotic liver disease (MASLD) remain unclear due to the absence of a standardized monitoring approach. This study aimed to (1) define improvement and worsening in children with MASLD, (2) estimate rates of improvement or deterioration with the standard of care (SOC) over 1 and 2 years, and (3) identify baseline and longitudinal factors associated with improvement or worsening. Approach and Results: Using data from 2 large randomized controlled trials, we derived definitions for composite improvement and worsening of MASLD based on associations between changes in ALT, GGT, and liver histology after 1 and 2 years. Improvement was defined as ≥40% decrease in ALT and ≥20% decrease in GGT and worsening as ≥20% increase in both ALT and GGT. We applied definitions to a cohort of 440 children with MASLD. After 1 year of SOC, 22% of children with MASLD showed improvement, increasing to 31% after 2 years. However, 20% showed worsening after both 1 and 2 years despite receiving SOC. Logistic regression analysis, employing stepwise model selection, identified changes in body mass index z-score and cholesterol to be most associated with improvement or deterioration. Conclusions: This study developed criteria for improvement and worsening in children with MASLD over 1 and 2 years of follow-up. With SOC, over one-quarter of children are likely to improve while one-fifth of children are likely to worsen. Targeting interventions that affect body mass index and lipid parameters may help improve MASLD over time.

22 July 2014 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
MFMark Fishbein
Mark Fishbein
KBKathryn Benton
Kathryn Benton
WSWilliam Struthers
William Struthers

1 July 2019 in The Journal of Pediatrics
Verified
Journal Article
Closed access
LLLauren M. Little
Lauren M. Little
KBKathryn Benton
Kathryn Benton
MMMaria Manuel-Rubio
Maria Manuel-Rubio
MSMiguel Saps
Miguel Saps
MFMark Fishbein
Mark Fishbein

12 December 2025 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Open access
LNLauren B. Nichols
Lauren B. Nichols
SOSebastian G. J. Oakes
Sebastian G. J. Oakes
CBCynthia Behling
Cynthia Behling
KAKathryn Harlow Adams
Kathryn Harlow Adams
MFMark H. Fishbein
Mark H. Fishbein
FCFor The Nash Crn
For The Nash Crn
Objectives: Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a prevalent disease in children. Vibration‐controlled transient elastography (VCTE) offers a noninvasive alternative to liver biopsy, using controlled attenuation parameter (CAP) to estimate steatosis and liver stiffness measurement (LSM) for fibrosis. However, pediatric data with histological validation are limited. This prospective, multicenter study evaluated the accuracy of CAP and LSM in pediatric MASLD. Methods: Children with histologically confirmed MASLD from the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Database 3 underwent VCTE within 6 months of liver biopsy. CAP was evaluated for correlation with steatosis grades, and LSM for correlation with fibrosis stages. The diagnostic performance of LSM in distinguishing fibrosis stages was analyzed using histological findings as the reference standard. Results: Among 92 children with MASLD (mean age 13 ± 3 years), CAP values were similar across steatosis grades (median 325, 310, and 323 dB/m for grades 1–3, respectively) and showed no significant correlation with histologic steatosis ( p = 0.422). Median LSM values increased with fibrosis stage (6.0–8.8 kPa), but significant differences were detected only between stage 0 and stage 3 fibrosis ( p = 0.037). For advanced fibrosis (stages 3–4), area under the receiver operating characteristic curve was 0.67, with sensitivity 67%, specificity 76%, positive predictive value 40%, and negative predictive value 90%. Conclusion: In this prospective, multicenter cohort, VCTE showed modest accuracy for grading steatosis or staging fibrosis in pediatric MASLD. Improved noninvasive methods are urgently needed for evaluation and monitoring in this population.